Waning antibodies to SARS-CoV-2 - Don't panic.
作者信息
Meyer Benjamin
机构信息
Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
出版信息
Lancet Reg Health Eur. 2021 May;4:100115. doi: 10.1016/j.lanepe.2021.100115. Epub 2021 May 5.
Abstract
摘要
相似文献
1
Waning antibodies to SARS-CoV-2 - Don't panic.针对新冠病毒的抗体水平下降——别恐慌。
Lancet Reg Health Eur. 2021 May;4:100115. doi: 10.1016/j.lanepe.2021.100115. Epub 2021 May 5.
2
Thrombotic complications of vaccination against SARS-CoV-2: what pharmacovigilance reports tell us - and what they don't.接种 SARS-CoV-2 疫苗后的血栓并发症：药物警戒报告告诉了我们什么——以及它们没有告诉我们什么。
Eur Respir J. 2021 Jul 1;58(1). doi: 10.1183/13993003.01111-2021. Print 2021 Jul.
3
Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection.无症状和有症状 SARS-CoV-2 感染的抗体反应减弱。
Emerg Infect Dis. 2021 Jan;27(1):327-9. doi: 10.3201/eid2701.203515. Epub 2020 Oct 13.
4
Don't panic: it's only panic disorder.
Harv Heart Lett. 1998 May;8(9):5-6.
5
Anti-coagulation in COVID-19: Dare I Give, Dare I Don't!新冠疫情中的抗凝治疗：我该用，还是不该用！
J Assoc Physicians India. 2021 Aug;69(8):11-12.
6
Managing children with brain tumors during the COVID-19 era: Don't stop the care!在新冠疫情时代管理患有脑肿瘤的儿童：不要停止护理！
Comput Struct Biotechnol J. 2021 Jan 12;19:705-709. doi: 10.1016/j.csbj.2021.01.005. eCollection 2021.
7
Don't Blame Hippocrates for Low Enrollment in Clinical Trials.不要因临床试验入组率低而责怪希波克拉底。
Am J Bioeth. 2021 Jan;21(1):1-3. doi: 10.1080/15265161.2021.1849503.
8
SARS-CoV-2 Membrane Glycoprotein M Triggers Apoptosis With the Assistance of Nucleocapsid Protein N in Cells.SARS-CoV-2 膜糖蛋白 M 在核衣壳蛋白 N 的协助下在细胞中引发细胞凋亡。
Front Cell Infect Microbiol. 2021 Aug 25;11:706252. doi: 10.3389/fcimb.2021.706252. eCollection 2021.
9
Influenza and COVID-19: Times Don't Get No Better.流感与新冠疫情：情况从未如此糟糕。
Ann Am Thorac Soc. 2021 Apr;18(4):586-587. doi: 10.1513/AnnalsATS.202011-1428ED.
10
Don't forget the trauma patient: lessons from a major trauma and major COVID centre.不要忘记创伤患者：来自一个重大创伤与重大新冠治疗中心的经验教训。
ANZ J Surg. 2021 Jun;91(6):1055-1056. doi: 10.1111/ans.16905. Epub 2021 May 24.
引用本文的文献
1
Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India.通过印度泰米尔纳德邦的两波 COVID 疫情，感染和疫苗接种对人群血清阳性率的贡献。
Sci Rep. 2024 Jan 24;14(1):2091. doi: 10.1038/s41598-023-50338-3.
2
Natural SARS-CoV-2 infection results in higher neutralization response against variants of concern compared with 2-dose BNT162b2 vaccination in kidney transplant recipients.与肾移植受者接种两剂BNT162b2疫苗相比，自然感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）会产生更高的针对变异株的中和反应。
Kidney Int. 2022 Mar;101(3):639-642. doi: 10.1016/j.kint.2021.12.009. Epub 2021 Dec 23.
3
Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks.腹膜透析和血液透析患者接种新冠疫苗后12周的纵向体液反应
Vaccines (Basel). 2021 Oct 4;9(10):1130. doi: 10.3390/vaccines9101130.
4
Waning antibodies in SARS-CoV-2 naïve vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers.未感染过新冠病毒的疫苗接种者体内抗体水平下降：对医护人员中mRNA-1273疫苗进行的持续免疫原性和疗效监测的三个月中期分析结果
J Infect. 2021 Sep;83(3):381-412. doi: 10.1016/j.jinf.2021.06.017. Epub 2021 Jun 20.
本文引用的文献
1
Evidence for antibody as a protective correlate for COVID-19 vaccines.针对 COVID-19 疫苗，抗体作为一种保护相关因素的证据。
Vaccine. 2021 Jul 22;39(32):4423-4428. doi: 10.1016/j.vaccine.2021.05.063. Epub 2021 May 24.
2
Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults.英国首次感染高峰后新冠病毒抗体阳性率：对36.5万名成年人的系列横断面研究
Lancet Reg Health Eur. 2021 May;4:100098. doi: 10.1016/j.lanepe.2021.100098. Epub 2021 May 2.
3
Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study.2020 年丹麦对 400 万 PCR 检测个体进行的 SARS-CoV-2 再感染保护评估：一项基于人群的观察性研究。
Lancet. 2021 Mar 27;397(10280):1204-1212. doi: 10.1016/S0140-6736(21)00575-4. Epub 2021 Mar 17.
4
Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study.全国性前瞻性研究中与症状相关的严重急性呼吸综合征冠状病毒 2 抗体持续存在。
Clin Infect Dis. 2021 Dec 16;73(12):2155-2162. doi: 10.1093/cid/ciab172.
5
Adaptive immunity to SARS-CoV-2 and COVID-19.对 SARS-CoV-2 和 COVID-19 的适应性免疫。
Cell. 2021 Feb 18;184(4):861-880. doi: 10.1016/j.cell.2021.01.007. Epub 2021 Jan 12.
6
Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study.医院工作人员感染新型冠状病毒2后前6个月抗体的持续存在情况：一项前瞻性纵向研究
Clin Microbiol Infect. 2021 Jan 20;27(5):784.e1-8. doi: 10.1016/j.cmi.2021.01.005.
7
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
8
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.针对 SARS-CoV-2 感染的强大中和抗体可长期存在。
Science. 2020 Dec 4;370(6521):1227-1230. doi: 10.1126/science.abd7728. Epub 2020 Oct 28.
9
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.西班牙 2020 年人群血清流行病学研究（ENE-COVID）：全国范围内基于人群的血清流行病学研究。
Lancet. 2020 Aug 22;396(10250):535-544. doi: 10.1016/S0140-6736(20)31483-5. Epub 2020 Jul 6.
10
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.瑞士日内瓦抗 SARS-CoV-2 IgG 抗体的血清流行率（SEROCoV-POP）：一项基于人群的研究。
Lancet. 2020 Aug 1;396(10247):313-319. doi: 10.1016/S0140-6736(20)31304-0. Epub 2020 Jun 11.
Zotero 插件